Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  The numbers reported in rows 5, 7, and 9 reflect the Reporting Person's beneficial ownership as of February 11, 2025. The percent reported in row 11 is calculated based on 42,042,645 shares of common stock, par value $0.001 per share, of the Issuer ("Common Stock"), which excludes 6,215,466 shares of non-voting Common Stock, outstanding as of November 1, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2024.


SCHEDULE 13G



 
GILEAD SCIENCES INC
 
Signature:/s/ Andrew Dickinson
Name/Title:Andrew Dickinson, Chief Financial Officer
Date:02/13/2025